Hemolytic-uremic syndrome epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
{{HUS}} | {{HUS}} | ||
{{CMG}}; {{AE}} {{S.G.}} | {{CMG}}; {{AE}} {{S.G.}}, {{AHS}} | ||
==Overview== | ==Overview== | ||
The highest proportion of HUS cases (15.3%) occurred among children aged <5 years. HUS affects female more than male and white race more than other races. Mortality is more commonly seen in elderly patients in which disease is less common but more dangerous | The highest proportion of [[Hemolytic-uremic syndrome|hemolytic uremic syndrome]] [[Hemolytic-uremic syndrome|(HUS)]] cases (15.3%) occurred among children aged <5 years. [[Hemolytic-uremic syndrome|HUS]] affects female more than male and white race more than other races. [[Mortality]] is more commonly seen in [[elderly]] [[Patient|patients]] in which [[disease]] is less common but more dangerous.The incidence of atypical [[Hemolytic-uremic syndrome|HUS]] in The United States of America is approximately two per million. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*In children less than 5 years of age, the incidence of HUS is approximately 8.5 per 100,000.<ref name="MeleRemuzzi2014">{{cite journal|last1=Mele|first1=Caterina|last2=Remuzzi|first2=Giuseppe|last3=Noris|first3=Marina|title=Hemolytic uremic syndrome|journal=Seminars in Immunopathology|volume=36|issue=4|year=2014|pages=399–420|issn=1863-2297|doi=10.1007/s00281-014-0416-x}}</ref> | *In children less than 5 years of age, the incidence of [[Hemolytic-uremic syndrome|hemolytic uremic syndrome]] [[HUS|(HUS)]] is approximately 8.5 per 100,000.<ref name="MeleRemuzzi2014">{{cite journal|last1=Mele|first1=Caterina|last2=Remuzzi|first2=Giuseppe|last3=Noris|first3=Marina|title=Hemolytic uremic syndrome|journal=Seminars in Immunopathology|volume=36|issue=4|year=2014|pages=399–420|issn=1863-2297|doi=10.1007/s00281-014-0416-x}}</ref> | ||
*The incidence of atypical [[Hemolytic-uremic syndrome|HUS]] in the United States of America is approximately 0.2 per 100,00 individuals.<ref name="pmid15168377">{{cite journal| author=Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Cnaan A et al.| title=Non-enteropathic hemolytic uremic syndrome: causes and short-term course. | journal=Am J Kidney Dis | year= 2004 | volume= 43 | issue= 6 | pages= 976-82 | pmid=15168377 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15168377 }}</ref> | |||
===Mortality rate=== | ===Mortality rate=== | ||
*In 2017, the mortality of hemolytic uremic syndrome (HUS) is estimated to approximately 10% .<ref>{{Cite journal | * [[Mortality]] is more commonly seen in [[elderly]] [[Patient|patients]] in which [[disease]] is less common but more dangerous.<ref name="pmid19827953">{{cite journal| author=Gould LH, Demma L, Jones TF, Hurd S, Vugia DJ, Smith K et al.| title=Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000-2006. | journal=Clin Infect Dis | year= 2009 | volume= 49 | issue= 10 | pages= 1480-5 | pmid=19827953 | doi=10.1086/644621 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19827953 }} </ref> | ||
*In 2017, the [[Mortality rate|mortality]] of [[Hemolytic-uremic syndrome|hemolytic uremic syndrome]] (HUS) is estimated to approximately 10%.<ref>{{Cite journal | |||
| author = [[Gregory Hall]], [[Shinichiro Kurosawa]] & [[Deborah J. Stearns-Kurosawa]] | | author = [[Gregory Hall]], [[Shinichiro Kurosawa]] & [[Deborah J. Stearns-Kurosawa]] | ||
| title = Shiga Toxin Therapeutics: Beyond Neutralization | | title = Shiga Toxin Therapeutics: Beyond Neutralization | ||
| Line 25: | Line 28: | ||
===Age=== | ===Age=== | ||
*Patients of all age groups may develop hemolytic uremic syndrome (HUS). | *Patients of all age groups may develop [[Hemolytic-uremic syndrome|hemolytic uremic syndrome]] ([[Hemolytic-uremic syndrome|HUS]]). | ||
*The incidence of HUS increases with age; the median age at diagnosis is younger than 5 years.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref> | *The incidence of [[Hemolytic-uremic syndrome|HUS]] increases with age; the median age at [[diagnosis]] is younger than 5 years.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref> | ||
*HUS commonly affects individuals younger than 5 years of age.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref> | *[[Hemolytic-uremic syndrome|HUS]] commonly affects individuals younger than 5 years of age.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref> | ||
===Race=== | ===Race=== | ||
*HUS usually affects individuals of the White race (82%).<ref name=":0" /> | *[[Hemolytic-uremic syndrome|HUS]] usually affects individuals of the White race (82%).<ref name=":0" /> | ||
===Gender=== | ===Gender=== | ||
*HUS affects female more than male. Approximately 59% of affected individuals are female.<ref name=":0">{{Cite journal | *[[HUS]] affects female more than male. Approximately 59% of affected individuals are female.<ref name=":0">{{Cite journal | ||
| author = [[Deirdra R. Terrell]], [[Sara K. Vesely]], [[Johanna A. Kremer Hovinga]], [[Bernhard Lammle]] & [[James N. George]] | | author = [[Deirdra R. Terrell]], [[Sara K. Vesely]], [[Johanna A. Kremer Hovinga]], [[Bernhard Lammle]] & [[James N. George]] | ||
| title = Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes | | title = Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes | ||
| Line 44: | Line 47: | ||
| pmid = 20799358 | | pmid = 20799358 | ||
}}</ref> | }}</ref> | ||
*[ | === '''Region''' === | ||
* In the United States and Western Europe, the reported annual [[Incidence (epidemiology)|incidence]] of [[Escherichia coli enteritis|STEC]] ([[Shiga toxin-producing E. coli|Shiga Toxin-Producing E.coli]]) [[Hemolytic-uremic syndrome|HUS]] is approximately two to three per 100,000 children less than five years of age.<ref name="pmid15728781">{{cite journal| author=Noris M, Remuzzi G| title=Hemolytic uremic syndrome. | journal=J Am Soc Nephrol | year= 2005 | volume= 16 | issue= 4 | pages= 1035-50 | pmid=15728781 | doi=10.1681/ASN.2004100861 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15728781 }} </ref> | |||
* Data on [[Pediatrics|paediatric]] [[Hemolytic-uremic syndrome|HUS]] established for some European countries (France, Germany, Austria and Italy) show an estimated prevalence of atypical HUS of 7 per million children in the whole of the European Community.<ref name="pmid19821824">{{cite journal| author=Taylor CM, Machin S, Wigmore SJ, Goodship TH, working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society| title=Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. | journal=Br J Haematol | year= 2010 | volume= 148 | issue= 1 | pages= 37-47 | pmid=19821824 | doi=10.1111/j.1365-2141.2009.07916.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19821824 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 15:15, 22 August 2018
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome epidemiology and demographics |
|
FDA on Hemolytic-uremic syndrome epidemiology and demographics |
|
CDC on Hemolytic-uremic syndrome epidemiology and demographics |
|
Hemolytic-uremic syndrome epidemiology and demographics in the news |
|
Blogs on Hemolytic-uremic syndrome epidemiology and demographics |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2], Anila Hussain, MD [3]
Overview
The highest proportion of hemolytic uremic syndrome (HUS) cases (15.3%) occurred among children aged <5 years. HUS affects female more than male and white race more than other races. Mortality is more commonly seen in elderly patients in which disease is less common but more dangerous.The incidence of atypical HUS in The United States of America is approximately two per million.
Epidemiology and Demographics
Incidence
- In children less than 5 years of age, the incidence of hemolytic uremic syndrome (HUS) is approximately 8.5 per 100,000.[1]
- The incidence of atypical HUS in the United States of America is approximately 0.2 per 100,00 individuals.[2]
Mortality rate
- Mortality is more commonly seen in elderly patients in which disease is less common but more dangerous.[3]
- In 2017, the mortality of hemolytic uremic syndrome (HUS) is estimated to approximately 10%.[4]
Age
- Patients of all age groups may develop hemolytic uremic syndrome (HUS).
- The incidence of HUS increases with age; the median age at diagnosis is younger than 5 years.[5]
Race
Gender
Region
- In the United States and Western Europe, the reported annual incidence of STEC (Shiga Toxin-Producing E.coli) HUS is approximately two to three per 100,000 children less than five years of age.[7]
- Data on paediatric HUS established for some European countries (France, Germany, Austria and Italy) show an estimated prevalence of atypical HUS of 7 per million children in the whole of the European Community.[8]
References
- ↑ Mele, Caterina; Remuzzi, Giuseppe; Noris, Marina (2014). "Hemolytic uremic syndrome". Seminars in Immunopathology. 36 (4): 399–420. doi:10.1007/s00281-014-0416-x. ISSN 1863-2297.
- ↑ Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Cnaan A; et al. (2004). "Non-enteropathic hemolytic uremic syndrome: causes and short-term course". Am J Kidney Dis. 43 (6): 976–82. PMID 15168377.
- ↑ Gould LH, Demma L, Jones TF, Hurd S, Vugia DJ, Smith K; et al. (2009). "Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000-2006". Clin Infect Dis. 49 (10): 1480–5. doi:10.1086/644621. PMID 19827953.
- ↑ Gregory Hall, Shinichiro Kurosawa & Deborah J. Stearns-Kurosawa (2017). "Shiga Toxin Therapeutics: Beyond Neutralization". Toxins. 9 (9). doi:10.3390/toxins9090291. PMID 28925976. Unknown parameter
|month=ignored (help) - ↑ 5.0 5.1 Karpman, Diana; Loos, Sebastian; Tati, Ramesh; Arvidsson, Ida (2017). "Haemolytic uraemic syndrome". Journal of Internal Medicine. 281 (2): 123–148. doi:10.1111/joim.12546. ISSN 0954-6820.
- ↑ 6.0 6.1 Deirdra R. Terrell, Sara K. Vesely, Johanna A. Kremer Hovinga, Bernhard Lammle & James N. George (2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". American journal of hematology. 85 (11): 844–847. doi:10.1002/ajh.21833. PMID 20799358. Unknown parameter
|month=ignored (help) - ↑ Noris M, Remuzzi G (2005). "Hemolytic uremic syndrome". J Am Soc Nephrol. 16 (4): 1035–50. doi:10.1681/ASN.2004100861. PMID 15728781.
- ↑ Taylor CM, Machin S, Wigmore SJ, Goodship TH, working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society (2010). "Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom". Br J Haematol. 148 (1): 37–47. doi:10.1111/j.1365-2141.2009.07916.x. PMID 19821824.